Liarozole dihydrochloride

• CAT Number: I010609
• CAS Number: 1883548-96-6
• Molecular Formula: C17H13ClN4.2HCl
• Molecular Weight: 381.69
• Purity: ≥95%
• Synonyms: Alternative Name: R-75251
• Solubility: Soluble to 100 mM in DMSO and to 100 mM in water
• Storage: Desiccate at RT
• IUPAC Name: 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;dihydrochloride
• InChI: InChI=1S/C17H13ClN4.2ClH/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15;;/h1-11,17H,(H,20,21);2*1H
• InChIKey: NKDMRTVUEJWCCQ-UHFFFAOYSA-N
• SMILES: C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4.Cl.Cl

Liarozole dihydrochloride(CAT: I010609) is a retinoic acid metabolism-blocking agent (RAMBA) that inhibits cytochrome P450-dependent enzymes, particularly CYP26, which are responsible for retinoic acid degradation. By increasing intracellular retinoic acid levels, it enhances its biological effects on cell differentiation and growth regulation. Liarozole dihydrochloride is widely studied in oncology and dermatology research, where it shows potential for treating cancer, psoriasis, and other disorders involving abnormal retinoid signaling. Its ability to modulate retinoic acid pathways also provides insights into the development of therapies targeting differentiation and proliferation in various diseases.